UNSPSC 51273017: Diperodon anhydrous

This classification denotes an anesthetic agent with the molecular formula C22H27N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIN4PYP84R, chemically known as 1,2-propanediol, 3-(1-piperidinyl)-, 1,2-bis(n-phenylcarbamate), but more generally known as diperodon anhydrous, which bears US NIH Compound Identifier 10831. European Medicines Agency schedules diperodon anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07207MIG.

Most nations, for tariff purposes, schedule diperodon anhydrous under HS 29333999. SMILES: C1CCC(CC1)NC(=O)OCC(CN2CCCCC2)OC(=O)NC3CCCCC3.

UNSPSC 51273017 Diperodon anhydrous is a Commodity code, but the recent state and local opportunities posted under it show minimal alignment with this specific pharmaceutical ingredient. Instead, the code captures broader pharmaceutical procurement activity including naloxone, generic multi-source drugs, and over-the-counter products through health departments, cooperative purchasing alliances, and state health agencies. State and local governments use this code tier to solicit finished pharmaceutical products, drug deactivation systems, and bulk generic medications for public health initiatives, emergency response, and employee health benefit programs rather than chemical precursors or raw pharmaceutical ingredients.

Activity spans Florida county health departments, state health commissions, and multistate cooperative purchasing organizations. Seminole County, Florida solicited 1,900 units of naloxone and 800 drug deactivation systems annually through IFB 60459723LAS (response deadline July 26, 2023), with quarterly deliveries to the county health building and FEMA funding cited as a potential source. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (response deadline March 26, 2026), requiring manufacturers to supply through three authorized wholesalers with awards effective July 1, 2026 and administered across participating state and local facilities including Oregon. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs to improve fulfillment efficiency and cost management outside traditional pharmacy benefit manager arrangements. The code shows most recent activity in Florida and across the multistate cooperative purchasing network; no dominant regional concentration is evident from the available opportunities.